Literature DB >> 1910031

Antitumor effect of recombinant human interleukin-2 on the growth of murine hemangioendothelioma D14 in nude mice: occurrence of large granular cells in the tumor.

Y Sakura1, T Houkan, K Ootsu, A Shino.   

Abstract

The antitumor effect of recombinant human interleukin-2 (rIL-2) on murine hemangioendothelioma D14 (D14) in female BALB/c-nu/nu mice was examined histologically. D14 cells which had been maintained in vitro were transplanted subcutaneously into nude mice on day 0 (1 x 10(7) cells/mouse). The mice with established tumor on day 28 received rIL-2 subcutaneously at a dose of 20 micrograms/mouse/day for 35 days. On day 63, the mice were killed, and the tumor, spleen and bone marrow were examined histologically. In the mice that had received rIL-2, tumor growth was significantly suppressed. Histologically, there was marked infiltration of large granular cells (about 15-30 microns in diameter) in the tumors. In the adjacent areas, there was a significant increase in the number of tumor cells showing karyorrhexis. The large granular cells (LGC) contained periodic acid Schiff-positive round granules in the cytoplasm and were stained positively for Thy-1.2 surface antigen. The LGC were also positive for asialo GM1 surface antigen but not for Lyt-1, Lyt-2 or IgG surface antigens. This evidence suggests that the LGC are lymphokine-activated killer-like cells which were derived from a natural killer cell lineage. The concomitant increases in the number of LGC and the number of cells showing karyorrhexis in the tumors of the mice treated with rIL-2 suggest that LGC play an important role in the destruction of tumor cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1910031      PMCID: PMC5918577          DOI: 10.1111/j.1349-7006.1991.tb01926.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  28 in total

1.  Purification and characterization of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  K Kato; T Yamada; K Kawahara; H Onda; T Asano; H Sugino; A Kakinuma
Journal:  Biochem Biophys Res Commun       Date:  1985-07-31       Impact factor: 3.575

2.  Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytes.

Authors:  S Hinuma; H Onda; K Naruo; Y Ichimori; M Koyama; K Tsukamoto
Journal:  Biochem Biophys Res Commun       Date:  1982-11-30       Impact factor: 3.575

3.  Therapeutic efficacy of human recombinant interleukin-2 (TGP-3) alone or in combination with cyclophosphamide and immunocompetent cells in allogeneic, semi-syngeneic, and syngeneic murine tumors.

Authors:  K Ootsu; K Gotoh; T Houkan
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Toxicity of human recombinant interleukin-2 in the mouse is mediated by interleukin-activated lymphocytes. Separation of efficacy and toxicity by selective lymphocyte subset depletion.

Authors:  T D Anderson; T J Hayes; M K Gately; J M Bontempo; L L Stern; G A Truitt
Journal:  Lab Invest       Date:  1988-11       Impact factor: 5.662

5.  Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.

Authors:  T Kalland; H Belfrage; P Bhiladvala; G Hedlund
Journal:  J Immunol       Date:  1987-06-01       Impact factor: 5.422

6.  Effect of recombinant interleukin 2 (R-IL2) on in vivo growth of murine myeloma X5563.

Authors:  R Maekawa; M Matsumoto; T Kitagawa; M Harada; K Sato
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

7.  Separation of recombinant human interleukin-2 and methionyl interleukin-2 produced in Escherichia coli.

Authors:  T Yamada; K Kato; K Kawahara; O Nishimura
Journal:  Biochem Biophys Res Commun       Date:  1986-03-28       Impact factor: 3.575

8.  Systemic administration of recombinant human interleukin-2 in mice.

Authors:  A E Chang; C L Hyatt; S A Rosenberg
Journal:  J Biol Response Mod       Date:  1984-10

9.  Lymphokine-activated killer (LAK) cells. II. Delineation of distinct murine LAK-precursor subpopulations.

Authors:  Z K Ballas; W Rasmussen; J K van Otegham
Journal:  J Immunol       Date:  1987-03-01       Impact factor: 5.422

10.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

Authors:  S A Rosenberg; J J Mulé; P J Spiess; C M Reichert; S L Schwarz
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  1 in total

1.  Antitumor effects of 5'-deoxy-5-fluorouridine in combination with recombinant human interleukin 2 on murine colon carcinoma 26.

Authors:  K Midoro; K Gotoh; T Houkan; K Yukishige; K Fujiwara; K Ootsu
Journal:  Jpn J Cancer Res       Date:  1997-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.